Cosmetic vs Drug: How FDA Treats SPF, Antiperspirant and Dandruff Imports

The cosmetic vs drug question decides which FDA program a beauty import enters under, and the answer is often not the one the brand expects. A tinted moisturizer with SPF 30 looks like a cosmetic on the shelf, but FDA regulates the sunscreen claim as an over-the-counter drug. The same applies to antiperspirants and anti-dandruff shampoos. A product listed under the Modernization of Cosmetics Regulation Act (MoCRA) can still be held at the port because it was entered as a cosmetic when FDA reads it as a drug, and for a drug-cosmetic the MoCRA listing is the wrong filing altogether.

This guide is for trade and compliance teams at beauty brands, K-beauty and J-beauty importers and retailer private-label programs. It covers the intended-use test, what MoCRA requires on the cosmetic side, the OTC monograph rules for cosmetic-drug products, the sunscreen monograph order announced on September 11, 2026, and how the ACE entry data differs between the two routes.

The Intended-Use Test That Separates Cosmetics From Drugs

FDA classifies a personal care product by what it is intended to do, and it reads intended use from the label, the claims and the way the product is marketed. A product that only cleanses, beautifies or changes appearance is a cosmetic. A product intended to prevent sunburn, reduce perspiration or control dandruff is a drug, even when it is sold on the same shelf, in the same packaging style, by the same brand.

Many products are both. A moisturizer with SPF is a cosmetic for its moisturizing function and a drug for its sun-protection function. Because it is subject to the drug requirements, section 613 of the FD&C Act exempts it from MoCRA registration, listing, adverse event reporting and safety substantiation, and it is listed with FDA as a drug instead. Its label still has to meet the drug labeling rules and the general cosmetic adulteration and misbranding provisions. In practice the drug side governs the import, because drug requirements at entry are the stricter ones and FDA will not release a drug product that lacks them.

Claims move products across the line in both directions. Removing a drug claim from a label can return a product to cosmetic status, but only if the claim disappears everywhere the product is sold, including marketplace listings and translated inserts. A Korean or Japanese product that is marketed at home with sun-protection or therapeutic claims keeps those claims in FDA’s eyes if the English labeling or US listing repeats them.

MoCRA Registration and Listing on the Cosmetic Side

MoCRA added sections 604 to 614 to Chapter VI of the Federal Food, Drug, and Cosmetic Act and created registration and listing duties for cosmetics that did not exist before. Facilities that manufacture or process cosmetics for the US market register with FDA, and the responsible person lists each product, including its ingredients. FDA began enforcing registration and listing on July 1, 2024.

The obligations that matter for an import program are these:

Exemptions and open rulemaking

Small businesses with average US cosmetic sales under $1,000,000 over the prior three years, adjusted for inflation, are exempt from registration and listing, but the exemption does not cover eye-area, injected, internal-use or long-wear appearance-altering products. FDA can suspend a facility registration where a product has a reasonable probability of causing serious adverse health consequences.

Several MoCRA rules are still pending. FDA withdrew its proposed talc asbestos-testing rule on November 28, 2025, and no proposed rule on cosmetic good manufacturing practice or fragrance-allergen labeling had been published in the Federal Register as of September 23, 2026. Importers should expect further rulemaking but should not build programs around proposals that do not yet exist.

• Facility registration, renewed every two years from the facility’s own initial registration date rather than in a fixed national window. New facilities register within 60 days of starting operations, and changes are updated within 60 days.
• Product listing by the responsible person, with new products listed within 120 days of marketing and listings updated annually.
• Serious adverse event reports submitted to FDA within 15 business days.
• Safety substantiation records kept for each product.
• A US agent for each foreign facility, with a limited role covering FDA communications, product questions and inspection scheduling.
• Submissions made through FDA’s Cosmetics Direct portal.

OTC Monograph Drugs: SPF, Antiperspirant and Anti-Dandruff

Sunscreens, antiperspirants and anti-dandruff products are marketed in the US under OTC monographs. A monograph fixes the active ingredients, strengths and labeling a product may use, and a cosmetic-drug product that relies on it is a drug for every regulatory purpose, including import.

That drug status carries requirements a cosmetic does not have. The foreign facility making the product must hold drug establishment registration before the product is imported, under 21 CFR 207.21(b), with an annual review each year between October 1 and December 31 and a single US agent. The product must be listed as a drug and carry a National Drug Code (NDC). And the formula and label must comply with the applicable OTC monograph. The facility also owes the annual OTC monograph drug facility fee; FDA treats OTC monograph drugs from a facility in arrears as misbranded.

A MoCRA registration does none of this. This is where beauty import programs go wrong: the brand registers its cosmetic facility, lists its whole range in Cosmetics Direct, SPF line included, and assumes it is covered. It is not. An SPF product is exempt from MoCRA listing and must instead be covered by drug establishment registration and a drug listing with an NDC, which are separate filings with separate data that FDA checks at entry.

Pending change to foreign drug registration

FDA published a proposed rule on foreign drug establishment registration on July 13, 2026 (91 FR 42888). It is a proposal, not a final rule, and the current registration requirements continue to apply until FDA finalizes any change.

The September 11, 2026 Sunscreen Monograph Order

FDA announced final order OTC000008-1 in the Federal Register on September 11, 2026 (91 FR 57892). The order removes two active ingredients, PABA (aminobenzoic acid) and trolamine salicylate, from the sunscreen monograph. A sunscreen that relies on either ingredient no longer fits the monograph and cannot be marketed on that basis.

For importers, the order turns into a formula screen. Every SPF product in the program, including tinted moisturizers, foundations, lip products and sprays that carry a sunscreen claim, should be checked against its ingredient list for these two actives. The check matters most for private-label and imported lines whose formulas were developed for other markets, where the ingredient decisions were made against a different rulebook.

Entry Data Differences Between Cosmetic and OTC Drug Lines

The cosmetic vs drug decision changes the FDA message set the broker transmits in ACE. The two routes use different programs and different mandatory data, and FDA’s screening compares what is declared against its registration databases.

On the cosmetic route, FDA’s March 10, 2026 ACE guidance still treats the cosmetic registration number (the COS Affirmation of Compliance) as optional, even though MoCRA registration is a legal obligation. Transmitting it anyway helps FDA match the shipment to the registered facility. On the OTC drug route, the drug registration (REG) and drug listing (DLS) codes are mandatory, and FDA states that an entry can be detained when the declared drug manufacturer cannot be found in its drug registration database.

What a refusal means for a drug line

Drug lines carry harsher outcomes when they go wrong. A drug from an unregistered or unlisted foreign establishment faces detention and refusal under section 801(a). FDA’s Regulatory Procedures Manual directs its staff not to permit relabeling as a way to bring a drug detained on a new drug charge into compliance, so a mislabeled SPF product may have no path to release. Refused goods must be exported or destroyed within 90 days, and FDA may destroy refused drugs valued at $2,500 or less without offering export.

Triage Before the Container Ships

The fix is a product-by-product triage run when the assortment is set, not when the vessel is at sea. Each SKU gets a route and a document set before booking.

How CargoTrans supports beauty importers

CargoTrans runs cosmetic and OTC drug entries through its customs brokerage team and supports route triage as part of trade compliance management. Warehousing, distribution and sector-specific logistics for beauty and chemical products are covered on our cosmetics and chemical distributors page. Foreign brands acting as their own importer of record should also review the rules for a non-resident importer, and importers sourcing from Seoul or Tokyo can check current duty exposure in our Korea tariffs and Japan tariffs guides.

• Sort every SKU by claim: cosmetic only, or cosmetic plus a sunscreen, antiperspirant or anti-dandruff claim.
• For cosmetic lines, confirm the MoCRA facility registration, the product listing and the foreign facility’s US agent, and send the registration number with the entry.
• For drug lines, confirm drug establishment registration, the NDC listing and the monograph fit before the PO is released.
• Screen every SPF formula for PABA and trolamine salicylate following the September 11, 2026 order.
• Check the US listing and translated labels for claims that move a cosmetic into drug territory.

Frequently Asked Questions